MMED Clinical Trials Team, Management team, Uplisting Full disclosure MMED is the only company I have an interest in currently in the psychedelic sector, and here are a few points as to why they are the horse I'm backing
-
Clinical Trials team is A1
- The two names linked to head their clinical trials team are Jason Summa and Jamie Freedman. One was the Director of Oncology for Clinical Project Scientists and the other was Associate Director of Oncology and Global Trial Leader, both for Janssen Research and Development. Janssen R&D is the R&D company for Johnson & Johnson. As some of you may know, Johnson 7 Johnson was recently included in the new psychedelic sector etf PSYK as they are looking into psychedelic medicines to add to their pharmaceutical portfolio.
- What this tells me is MMED has direct connections to sell any products they develop to Johnson & Johnson and essentially into the hands of big pharma. Why swim against the current and risk having these companies lobby against you and shut you down, when instead you can forge connections with them and create a profitable pipeline to sell or license all of your drugs that show positive results through clinical trials. Obviously Johnson & Johnson would have respect for, and invest in products developed by former Directors of their own R&D company.
2) They have the right marketing and financiers on their staff
- Bruce Linton took Canopy to a $22B valuation at its peak, the guy understands how to market securities and how to get institutional capital injected into the companies he works for. He is a board chair, and I expect his influence to be all over this company as they look for NASDAQ listing and to have their shares added by institutional investors. They already have CIBC Capital Markets on board, making them the only psych company to have a big 5 Canadian Bank to be included in their financing deal. Major plus.
- Kevin O'Leary is heavily involved in this company, to the point he is doing interviews and going on the road to market and promote the future growth of MMED. He wouldn't stake his reputation as well as his capital if he didn't see something in this company. The only business man in this industry I respect more than Mr. Wonderful would be Peter Thiel, who has recently invested tons of money into ATAI, his own psychedelic medicine company. In a recent interview Kevin O'Leary said if he was indexing the industry right now he would buy MMED for 45%, ATAI for 40% and CMPS for 15% as they are the major players and likely to have the most success in the industry.
3) They haven't even gotten their uplisting to the NASDAQ yet
- From all the DD I have done, it seems like this will be a sure shot, by the latest it will be done in early March. Likely a lot sooner. As soon as this happens there will be a huge appreciation in the share price. As mentioned before, ATAI, MMED and CMPS are the best companies in the industry. CMPS is already on the NASDAQ and has seen its 120% increase within the first week of listing. ATAI is not public yet, but rumour is it will be listed directly to the NASDAQ so it will be tough to get in early enough to see this rise in share price. MMED is the only one of the 3 that is public already, and has not yet been granted NASDAQ access. You can grab this now cheap on the NEO and benefit from the potential uplisting
These are the main points I see for near term price appreciation. As well as them being the furthest along in clinical trials and in FDA compliance. If I was picking one horse right now for the psychs race, it would be MMED.
I discuss these points in my most recent podcast episode. If you found any of this information useful I would really appreciate if you could check out my most recent episode where I go a little further into detail on these and a few more points.
Cheers, and thanks in advance to anyone who takes the 15 minutes to give it a listen!
https://anchor.fm/10-minute-investing/episodes/008---MMED-Overview-epcb01